Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01063478 · ClinicalTrials.gov registry record · Phase 1
Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC
A Phase 1 study, sponsored by University of Chicago.
- Terminated
- Registry status
- Phase 1
- Development phase
- 3
- Enrollment target
NCT01063478 is a Phase 1 study that was terminated before completion, run by University of Chicago. The registered enrollment target is 3 participants.
The verdict
NCT01063478, a Phase 1 study, was terminated before completion, sponsored by University of Chicago.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 3 participants
- Enrollment target
Study Summary
The purpose of this study is to understand the effects (good and/or bad) of the addition of RAD001 to standard radiation and chemotherapy (cisplatin and pemetrexed) for patients with non-small cell lung cancer.
Interventions
- DRUG RAD001 (in addition to standard radiation and chemotherapy)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2010-02 |
| Est. Completion | 2012-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01063478
The ClinicalTrials.gov registry entry for NCT01063478 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which RAD001 (in addition to standard radiation and chemotherapy) is the first listed.
NCT01063478 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01063478 about?
NCT01063478 is a clinical study titled "Dose Escalation Study of RAD001 in Combination w/Chemotherapy & Radiation in Patients With NSCLC". The purpose of this study is to understand the effects (good and/or bad) of the addition of RAD001 to standard radiation and chemotherapy (cisplatin and pemetrexed) for patients with non-small cell lung cancer.
What is the current status of trial NCT01063478?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 3 participants. The study started on 2010-02. Estimated completion is 2012-01.
What interventions are being tested in trial NCT01063478?
The interventions under investigation include: RAD001 (in addition to standard radiation and chemotherapy) (DRUG).
Who is sponsoring clinical trial NCT01063478?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.